Feb 13, 2025 8:00am EST RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
Feb 11, 2025 7:00am EST RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Feb 06, 2025 8:49pm EST RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
Jan 27, 2025 8:00am EST RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
Jan 08, 2025 8:00am EST RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
Dec 30, 2024 8:00am EST RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
Dec 11, 2024 8:00am EST RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
Dec 10, 2024 8:00am EST RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
Dec 05, 2024 8:00am EST RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
